1 1

PE 22-28

PE 22-28

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$55.00
$55.00
Sale Sold out
Shipping calculated at checkout.

PE-22-28 — Research Peptide

Professional-grade PE-22-28 supplied for qualified research. Structured page includes identifiers, sequence, background, study highlights, potential research applications, synergy, and responsible-use notes.

Identifiers
  • CAS / CID: TBD
  • Synonyms: PE-22-28 (enter lab synonyms if applicable)
  • Sequence: TBD (single-letter or full; e.g., Gly-His-Lys)
  • Molecular Weight: TBD
  • Form: Lyophilized powder (typical)
Origin & Background

Summarize the origin: discovery context (e.g., fragment/analog of a parent protein), original research aim (receptor targeting, signaling motif, stability), and known areas of preclinical exploration. Keep to neutral, research-oriented language.

  • First reported/characterized by: TBD (Year)
  • Primary research focus: TBD (e.g., neurotrophic signaling / metabolic modulation / anti-inflammatory)
Handling
  • Storage (powder): −20 °C, desiccated, away from light.
  • Stability: Avoid repeated freeze-thaw; aliquot as needed.
  • Reconstitution: Provided for qualified research labs; **no usage instructions** are supplied for human/clinical administration.

Key Study Highlights (Plain-English Summaries)

Mechanism / Target Pathways
  • Proposed target(s): TBD (e.g., receptor binding, enzyme modulation, peptide–protein interaction).
  • Downstream signals: TBD (e.g., cAMP/PKA, MAPK/ERK, PI3K/AKT), based on preclinical models.
  • Notes: Clarify whether data are in vitro, ex vivo, or in vivo models; avoid clinical claims.
Preclinical Outcomes Reported
  • Model: TBD (cell line/animal model). Finding: brief, outcome-oriented phrasing (e.g., “supported marker X,” “modulated Y”).
  • Model: TBD. Finding: dose/interval context if available (keep general).
  • Formulation notes: route, vehicle, stability comments if reported.

Potential Research Applications

  • Pathway exploration: TBD (e.g., receptor/ligand studies, signaling cascade mapping).
  • Comparative assays: head-to-head vs. parent peptide/fragments.
  • Structure–activity relationships (SAR): substitutions, cyclization, pegylation, stability testing.

For laboratory research only. Not for diagnostic, therapeutic, or human use.

Synergistic / Comparator Peptides

Comparator A

Parent or reference peptide to benchmark activity.

Synergy B

Peptide targeting complementary pathway to test combined signaling.

Control C

Negative/control analog or scrambled sequence for assay design.

Known Concerns & Responsible Use

  • Data stage: Early-stage/preclinical; limited translational evidence.
  • Stability/specificity: Validate sequence integrity, purity, and potential off-target binding.
  • Compliance: Research-only; no reconstitution/administration instructions provided.

Specifications

Appearance White to off-white lyophilized powder
Purity (HPLC/MS) ≥ 99% 
Sequence TBD
Solubility TBD (e.g., water, PBS, dilute acid)
Storage −20 °C (powder); aliquot upon receipt; protect from light
Shipping Ambient or cold-chain depending on climate/season
Contents [e.g., 5 mg / 10 mg vial]

PE-22-28 Research Peptide | Sequence, Origin, Studies, Applications | High-Purity ≥99% | Base Peptides

Keywords: PE-22-28 peptide, PE 22-28 sequence, research peptide fragment, high purity peptide, HPLC MS tested peptide, Base Peptides COA.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping